UFLEX Limited has informed the Exchange about Transcript
UFLEX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 0.7 pts more than its Packaging peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
UFLEX held its Q3 and 9M FY26 earnings call. Q3 FY26 revenue fell 3.8% YoY to Rs. 363 crore, but normalized EBITDA rose 12.8% sequentially to Rs. 439.5 crore with margins expanding 200 bps QoQ to 12.1%; 9M FY26 PAT swung to Rs. 121 crore from a Rs. 26 crore loss a year ago. Management cited US tariff uncertainty and India's GST transition as the main headwinds, but said pricing has since recovered (BOPET ~Rs. 110/kg, BOPP ~Rs. 120-121/kg) and FY26 EBITDA should land in the Rs. 1,800–1,850 crore range at roughly 12% margin. Three large projects — Egypt aseptic plant (12 bn packs), India recycling plant (40,000 tons) and Mexico WPP plant (80 bn bags) — are nearing commissioning and are expected to add Rs. 2,000–2,500 crore of revenue at high-teens margin at full utilization. Aseptic packaging volumes are guided at ~8.5 bn packs for FY26, and management said debt leverage has peaked at current levels with cost of funds (currently 6.9–7%) targeted to come down.
An improving margin trajectory into FY27, supported by new project commissioning and easing tariff pressure, is the key positive takeaway, but management's refusal to give a specific FY27 aseptic volume number and its vague stance on absolute debt reduction (~Rs. 8,000 crore net debt, no plan to bring it down in the near term) may keep the stock from re-rating until leverage and earnings visibility improve.